many of the defects coevolve during the pathogenesis of T2D and are demonstrable even at the stage of prediabetes (Figure 1.6).4,11,13,14
References
1. DCCT/EDIC Research Group. Modern-day clinical course of type 1 diabetes mellitus after 30 years’ duration: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications and Pittsburgh epidemiology of diabetes complications experience (1983–2005). Arch Intern Med 2009;169:1307–1316
2. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–853
3. American Diabetes Association. Standards of medical care in diabetes–2016. Diabetes Care 2015;39(Suppl. 1):S4–S104
4. Dagogo-Jack S, Edeoga C, Ebenibo S, Nyenwe E, Wan J; for the Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) Research Group. Lack of racial disparity in incident prediabetes and glycemic progression among black and white offspring of parents with type 2 diabetes: the Pathobiology of Prediabetes in a Biracial Cohort (POP-ABC) Study. J Clin Endocrinol 2014;99:E1078–E1087
5. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393–403
6. Atkinson MA, Eisenbarth GS, Michels AW. Type 1 diabetes. Lancet 2014;383:69–82
7. Granner DK, O’Brien RM. Molecular physiology and genetics of NIDDM. Diabetes Care 1992;15:369–388
8. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kahn CR. Role of glucose and insulin resistance in the development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925–929
9. Hivert MF, Jablonski KA, Perreault L, Saxena R, McAteer JB, Franks PW, Hamman RF, Kahn SE, Haffner S; DIAGRAM Consortium, Meigs JB, Altshuler D, Knowler WC, Florez JC; Diabetes Prevention Program Research Group. Updated genetic score based on 34 confirmed type 2 diabetes loci is associated with diabetes incidence and regression to normoglycemia in the Diabetes Prevention Program. Diabetes 2011;60:1340–1348
10. Dagogo-Jack S. Predicting diabetes: our relentless quest for genomic nuggets. Diabetes Care 2012;35:193–195
11. Dagogo-Jack S, Santiago JV. Pathophysiology of type 2 diabetes and modes of action of therapeutic interventions. Arch Intern Med 1997;157:1802–1817
12. Moneva M, Dagogo-Jack S. Multiple drug targets in the management of type 2 diabetes mellitus. Current Drug Targets 2002;3:203–221
13a. Defronzo RA. Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 2009;58:773–795
13b. DeFronzo RA. Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009. Diabetologia 2010;53:1270–1287
14. Weyer C, Bogardus C, Mott DM, Pratley R. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–794
15. Centers for Disease Control and Prevention. National diabetes statistics report, 2014. Available from http://www.cdc.gov/diabetes/pubs/statsreport14/national-diabetes-report-web.pdf. Accessed 5 January 2016
16. Cowie CC, Rust KF, Byrd-Holt DD, Gregg EW, Ford ES, Geiss LS, Bainbridge KE, Fradkin JE. Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988–2006. Diabetes Care 2010;33:562–568
17. Menke A, Rust KF, Savage PJ, Cowie CC. Hemoglobin A1c, fasting plasma glucose, and 2-hour plasma glucose distributions in US population subgroups: NHANES 2005–2010. Ann Epidemiol 2014;24:83–89
18. Gale EA, Gillespie KM. Diabetes and gender. Diabetologia 200;44:3–15
19. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047–1053
20. Centers for Disease Control and Prevention. National Health Interview Survey (NHIS). Available from http://www.cdc.gov/nchs/nhis.htm. Accessed 5 July 2015
21. Centers for Disease Control and Prevention. 2008 National Center for Health Statistics: National Health and Nutrition Examination Survey 2005–2006, 2008. Available from http://www.cdc.gov/nchs/about/major/nhanes/nhanes2005-2006/nhanes05_06.htm. Accessed 5 July 2015
22. Perreault L, Ma Y, Dagogo-Jack S, Horton E, Marrero D, Crandall J, Barrett-Connor E; Diabetes Prevention Program. Sex differences in diabetes risk and the effect of intensive lifestyle modification in the Diabetes Prevention Program. Diabetes Care 2008;31:1416–1421
23. Knowler WC, Bennett PH, Hamman RF, Miller M. Diabetes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol 1978;108:497–505
24. Centers for Disease Control and Prevention. 2011 National diabetes fact sheet. Diagnosed and undiagnosed diabetes in the United States, all ages, 2010. Available from http://www.cdc.gov/diabetes/pubs/estimates11.htm. Accessed 5 July 2015
25. Brancati FL, Kao WH, Folsom AR, Watson RL, Szklo M. Incident type 2 diabetes mellitus in African American and white adults: the Atherosclerosis Risk in Communities Study. JAMA 2000;283:2253–2259
26. Harris MI. Racial and ethnic differences in health care access and health outcomes for adults with type 2 diabetes. Diabetes Care 2001;24:454–459
27. Cowie CC, Rust KF, Byrd-Holt DD, Eberhardt MS, Flegal KM, Engelgau MM, Saydah SH, Williams DE, Geiss LS, Gregg EW. Prevalence of diabetes and impaired fasting glucose in adults in the U.S. population: National Health and Nutrition Examination Survey 1999–2002. Diabetes Care 2006;29:1263–1268
28. Cowie CC, Rust KF, Ford ES, Eberhardt MS, Byrd-Holt DD, Li C, Williams DE, Gregg EW, Bainbridge KE, Saydah SH, Geiss LS. Full accounting of diabetes and pre-diabetes in the U.S. population in 1988–1994 and 2005–2006. Diabetes Care 2009;32:287–294
29. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009;374:1677–1686
30. Rodbard HW, Bays HE, Gavin JR 3rd, et al. Rate and risk predictors for development of self-reported type-2 diabetes mellitus over a 5-year period: the SHIELD study. Int J Clin Pract 2012;66:684–691
31. Rodbard HW, Bays HE, Gavin JR 3rd, Green AJ, Bazata DD, Lewis SJ, Fox KM, Reed ML, Grandy S. Rate and risk predictors for development of self-reported type-2 diabetes mellitus over a 5-year period: the SHIELD study. Int J Clin Pract 2012;66:684–691
32. Selvin E, Parrinello CM, Sacks DB, Coresh J. Trends in prevalence and control of diabetes in the U.S., 1988–1994 and 1999–2010. Ann Intern Med 2014;160:517–525
33. Dagogo-Jack S. Pitfalls in the use of HbA1c as a diagnostic test: the ethnic conundrum. Nat Rev Endocrinol 2010;6:589–593
34. Egede LE, Dagogo-Jack S. Epidemiology of type 2 diabetes: focus on ethnic minorities. Med Clin N Am 2005;89:949–975
35. Karter AJ, Ferrara A, Liu JY, Moffet HH, Ackerson LM, Selby JV. Ethnic disparities in diabetic complications in an insured population. JAMA 2002;287:2519–2527
36. Rasmussen BB, Holmbäck UC, Volpi E, et al. Malonyl coenzyme A and the regulation of functional carnitine palmitoyltransferase-1